title: Toxicity of hemoglobin solutions: hemoglobin is a lipopolysaccharide (LPS) binding protein which enhances LPS biological activity.
abstract: Administration of alpha alpha-crosslinked stroma-free hemoglobin (SFH) as a cell-free resuscitation fluid is associated with multiple organ toxicities. Many of these toxicities are characteristic of the pathophysiological effects of bacterial endotoxins (lipopolysaccharide, LPS). To better understand the potential role of LPS in the observed in vivo toxicities of SFH, we examined mixtures of SFH and E. coli LPS for evidence of LPS-SFH complex formation. LPS-SFH complexes were demonstrated by three techniques: ultrafiltration through 300 kDa cut-off membranes, which distinguished LPS in complexes (87-89% < 300 kDa) from LPS alone (90% > 300 kDa); density centrifugation through 5% sucrose, which distinguished denser LPS alone from LPS-SFH complexes; and precipitation by 67% ethanol, which demonstrated 2-3 fold increased precipitability of complexes compared to SFH alone. Interaction of LPS with SFH was also associated with markedly increased biological activity of LPS, as manifested by enhancement of LPS activation of Limulus amebocyte lysate (LAL), increased release of human mononuclear cell tissue factor, and enhanced production of cultured human endothelial cell tissue factor. These results demonstrated that hemoglobin can serve as an endotoxin binding protein, and that this interaction results in the alteration of several LPS physical characteristics and enhancement of LPS biological activities.
authors.affiliation: Department of Laboratory Medicine, University of California School of Medicine, San Francisco.
authors.forename: R I
authors.initials: RI
authors.lastname: Roth
authors.forename: W
authors.initials: W
authors.lastname: Kaca
mesh_terms: D000209:Acute-Phase Proteins; D000818:Animals; D001802:Blood Substitutes / Q000378:metabolism* / Q000633:toxicity*; D002352:Carrier Proteins / Q000378:metabolism* / Q000633:toxicity*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism / Q000633:toxicity; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008033:Limulus Test; D008070:Lipopolysaccharides / Q000737:chemistry / Q000378:metabolism* / Q000633:toxicity*; D008562:Membrane Glycoproteins; D011485:Protein Binding; D012151:Resuscitation / Q000009:adverse effects; D013925:Thromboplastin / Q000096:biosynthesis; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D001802:Blood Substitutes; D002352:Carrier Proteins; D006454:Hemoglobins; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D013925:Thromboplastin; D000099231:Lipopolysaccharide-Binding Protein; C016484:hemoglobin, stroma free